$RAIN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Rain Therapeutics Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Rain Therapeutics Inc.. Get notifications about new insider transactions in Rain Therapeutics Inc. for free.
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 18 2021 | RAIN | Rain Therapeutics ... | Wolff Stefani | Director | Option Exercise | A | 15.33 | 24,000 | 367,920 | 24,000 | |
May 17 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | P | 14.26 | 3,474 | 49,544 | 91,700 | 88.2 K to 91.7 K (+3.94 %) |
May 17 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | P | 14.26 | 22,721 | 324,036 | 555,105 | 532.4 K to 555.1 K (+4.27 %) |
May 17 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | P | 14.26 | 31,805 | 453,587 | 761,537 | 729.7 K to 761.5 K (+4.36 %) |
May 14 2021 | RAIN | Rain Therapeutics ... | Cabatuan Nelson | See Remarks | Option Exercise | A | 15.91 | 6,000 | 95,460 | 6,000 | |
Apr 29 2021 | RAIN | Rain Therapeutics ... | Cormorant Asset Management, LP | Option Exercise | C | 0.00 | 2,512,561 | 0 | 0 | ||
Apr 29 2021 | RAIN | Rain Therapeutics ... | Cormorant Asset Management, LP | Buy | P | 17.00 | 450,000 | 7,650,000 | 2,776,657 | 2.3 M to 2.8 M (+19.34 %) | |
Apr 29 2021 | RAIN | Rain Therapeutics ... | Cormorant Asset Management, LP | Buy | C | 0.00 | 2,326,657 | 0 | 2,326,657 | 0 to 2.3 M | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 1,195,792 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 949,992 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 17.00 | 550,000 | 9,350,000 | 2,537,019 | 2 M to 2.5 M (+27.68 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,107,316 | 0 | 1,987,019 | 879.7 K to 2 M (+125.87 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 879,703 | 0 | 879,703 | 0 to 879.7 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 134,515 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 152,176 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 17,390 | 0 | 152,176 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 837,397 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 553,359 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 84,350 | 0 | 553,359 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,068,554 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 832,261 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 115,293 | 0 | 832,261 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 134,515 | 0 | 286,691 | 152.2 K to 286.7 K (+88.39 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 152,176 | 0 | 152,176 | 0 to 152.2 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 1,747 | 26,032 | 88,226 | 86.5 K to 88.2 K (+2.02 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 6,141 | 97,817 | 86,479 | 80.3 K to 86.5 K (+7.64 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 62,948 | 1,070,116 | 80,338 | 17.4 K to 80.3 K (+361.98 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 17,390 | 0 | 17,390 | 0 to 17.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 837,397 | 0 | 1,390,756 | 553.4 K to 1.4 M (+151.33 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 553,359 | 0 | 553,359 | 0 to 553.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 10,876 | 162,062 | 532,384 | 521.5 K to 532.4 K (+2.09 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 38,858 | 618,950 | 521,508 | 482.7 K to 521.5 K (+8.05 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 398,300 | 6,771,100 | 482,650 | 84.4 K to 482.7 K (+472.20 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 134,515 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 84,350 | 0 | 84,350 | 0 to 84.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 152,176 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 1,068,554 | 0 | 1,900,815 | 832.3 K to 1.9 M (+128.39 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 17,390 | 0 | 152,176 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 832,261 | 0 | 832,261 | 0 to 832.3 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 837,397 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 14,790 | 220,384 | 729,732 | 714.9 K to 729.7 K (+2.07 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 553,359 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 53,303 | 849,037 | 714,942 | 661.6 K to 714.9 K (+8.06 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 84,350 | 0 | 553,359 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 546,346 | 9,287,882 | 661,639 | 115.3 K to 661.6 K (+473.88 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,068,554 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 115,293 | 0 | 115,293 | 0 to 115.3 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 832,261 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 115,293 | 0 | 832,261 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 134,515 | 0 | 286,691 | 152.2 K to 286.7 K (+88.39 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 152,176 | 0 | 152,176 | 0 to 152.2 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 1,747 | 26,032 | 88,226 | 86.5 K to 88.2 K (+2.02 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 6,141 | 97,817 | 86,479 | 80.3 K to 86.5 K (+7.64 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 62,948 | 1,070,116 | 80,338 | 17.4 K to 80.3 K (+361.98 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 17,390 | 0 | 17,390 | 0 to 17.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 837,397 | 0 | 1,390,756 | 553.4 K to 1.4 M (+151.33 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 553,359 | 0 | 553,359 | 0 to 553.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 10,876 | 162,062 | 532,384 | 521.5 K to 532.4 K (+2.09 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 38,858 | 618,950 | 521,508 | 482.7 K to 521.5 K (+8.05 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 398,300 | 6,771,100 | 482,650 | 84.4 K to 482.7 K (+472.20 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 84,350 | 0 | 84,350 | 0 to 84.4 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 1,068,554 | 0 | 1,900,815 | 832.3 K to 1.9 M (+128.39 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 832,261 | 0 | 832,261 | 0 to 832.3 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 14.90 | 14,790 | 220,384 | 729,732 | 714.9 K to 729.7 K (+2.07 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 15.93 | 53,303 | 849,037 | 714,942 | 661.6 K to 714.9 K (+8.06 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Grant | A | 17.00 | 546,346 | 9,287,882 | 661,639 | 115.3 K to 661.6 K (+473.88 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 115,293 | 0 | 115,293 | 0 to 115.3 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Boxer Capital, LLC | Director | Option Exercise | C | 0.00 | 3,022,489 | 0 | 79,726 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Boxer Capital, LLC | Director | Option Exercise | C | 0.00 | 3,263,986 | 0 | 3,022,489 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Boxer Capital, LLC | Director | Buy | P | 17.00 | 1,025,000 | 17,425,000 | 1,175,000 | 150 K to 1.2 M (+683.33 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Boxer Capital, LLC | Director | Buy | P | 16.27 | 125,000 | 2,033,750 | 150,000 | 25 K to 150 K (+500.00 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Boxer Capital, LLC | Director | Buy | P | 15.58 | 25,000 | 389,500 | 25,000 | 0 to 25 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Option Exercise | C | 0.00 | 79,726 | 0 | 79,726 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Option Exercise | C | 0.00 | 3,022,489 | 0 | 3,022,489 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Option Exercise | C | 0.00 | 86,097 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Option Exercise | C | 0.00 | 3,263,986 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Buy | P | 17.00 | 1,025,000 | 17,425,000 | 1,175,000 | 150 K to 1.2 M (+683.33 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Buy | P | 16.27 | 125,000 | 2,033,750 | 150,000 | 25 K to 150 K (+500.00 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Davis Aaron I. | Director | Buy | P | 15.58 | 25,000 | 389,500 | 25,000 | 0 to 25 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Radovich Peter | Director | Option Exercise | C | 0.00 | 9,500 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Radovich Peter | Director | Buy | C | 0.00 | 8,796 | 0 | 8,796 | 0 to 8.8 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 578,397 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 189,998 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 535,601 | 0 | 836,540 | 300.9 K to 836.5 K (+177.98 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 175,939 | 0 | 300,939 | 125 K to 300.9 K (+140.75 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Buy | P | 15.78 | 5,000 | 78,900 | 125,000 | 120 K to 125 K (+4.17 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | BERGER FRANKLIN M | Director | Buy | P | 17.00 | 120,000 | 2,040,000 | 120,000 | 0 to 120 K |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Doebele Robert | EVP, Chief Scientif ... | Option Exercise | C | 0.00 | 5,327 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Doebele Robert | EVP, Chief Scientif ... | Buy | C | 0.00 | 4,932 | 0 | 467,937 | 463 K to 467.9 K (+1.07 %) |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Vellanki Avanish | President and CEO | Option Exercise | C | 0.00 | 12,108 | 0 | 0 | |
Apr 27 2021 | RAIN | Rain Therapeutics ... | Vellanki Avanish | President and CEO | Buy | C | 0.00 | 11,212 | 0 | 2,372,541 | 2.4 M to 2.4 M (+0.47 %) |
Page: 1